




E286: Synthesis of Anthracimycin and Anthracimycin B




E286: Synthesis of Anthracimycin and Anthracimycin B



EX286: Process Development of RLY-2139




Bag, S.; Che, A. Q.; Lescarbeau, A.; Jones, D.; Karnati, V.; He, J.; Taylor, A. M.; Heap, C.; Briggs, T.; Liang, J. C.; Larrow, J.; Kong, L.; Zhang, J.; Guo, S.; Wang, L.; Song, L.; Singh, S. Process Development and Scale-Up of RLY-2139: A Selective CDK2 Inhibitor Targeting ER+/HER2- Breast Cancer. *Org. Process Res. Dev.* **2026**, *30* (2), 268–279. <https://doi.org/10.1021/acs.oprd.5c00342>.




University
of Basel

Sparr Group Seminar
25/03/26
Suman Dana

EX286: Process Development of RLY-2139



Bag, S.; Che, A. Q.; Lescarbeau, A.; Jones, D.; Karnati, V.; He, J.; Taylor, A. M.; Heap, C.; Briggs, T.; Liang, J. C.; Larrow, J.; Kong, L.; Zhang, J.; Guo, S.; Wang, L.; Song, L.; Singh, S. Process Development and Scale-Up of RLY-2139: A Selective CDK2 Inhibitor Targeting ER+/HER2- Breast Cancer. *Org. Process Res. Dev.* **2026**, *30* (2), 268–279. <https://doi.org/10.1021/acs.oprd.5c00342>.



University
of Basel

Sparr Group Seminar
25/03/26
Suman Dana